Introduction: evidence for the role of the polyol pathway in the pathophysiology of diabetic complications
Related Experiment Videos
Metabolism: Clinical and Experimental
|April 1, 1986
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Massive Dracunculus insignis infection in a dog.
Journal of the American Veterinary Medical Association·1999
Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors.
Journal of medicinal chemistry·1992
Orally active aldose reductase inhibitors: indazoleacetic, oxopyridazineacetic, and oxopyridopyridazineacetic acid derivatives.
Journal of medicinal chemistry·1992
Potent, orally active aldose reductase inhibitors related to zopolrestat: surrogates for benzothiazole side chain.
Journal of medicinal chemistry·1992
In-vitro assessment of a hypersensitivity syndrome associated with sorbinil.
Annals of internal medicine·1991
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
Journal of medicinal chemistry·1991
A 2026 update on the epidemiology of obesity, related cardio-kidney-liver metabolic complications and beyond; a call to action.
Metabolism: clinical and experimental·2026
Therapeutic potential of lactate-based interventions in cardiac disease: metabolic and hemodynamic mechanisms.
Metabolism: clinical and experimental·2026
miR-150-5p promotes MASH progression through regulation of CTH-associated sulfur and redox metabolism.
Metabolism: clinical and experimental·2026
MINDY1 drives metabolic-immune crosstalk via OGT-UGP2-UDPG axis to promote immunosuppressive macrophage reprogramming.
Metabolism: clinical and experimental·2026
Depot-specific molecular remodelling of human adipose tissue and liver following bariatric surgery revealed by longitudinal multi-omic profiling.
Metabolism: clinical and experimental·2026
P7C3: A novel multi-target therapeutic strategy to combat disuse-related bone loss in space and on earth.
Metabolism: clinical and experimental·2026
Pharmacogenomic Markers of Disease Susceptibility and Glucocorticoid Responsiveness in Pemphigus Vulgaris.
Indian dermatology online journal·2026
Glucagon-Like Peptide-1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction.
Journal of the American Heart Association·2026
From metabolic therapy to addiction care: a clinical pharmacology roadmap for GLP-1 receptor agonists in substance use disorders.
Expert review of clinical pharmacology·2026
Perioperative management of GLP-1 receptor agonists and SGLT2 inhibitors: An updated review for anesthesiologists.
Saudi journal of anaesthesia·2026